Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron Pharmaceuticals topped analyst forecasts for first-quarter revenue and earnings Wednesday, powered by gains from Dupixent and Libtayo that balanced out softer Eylea sales. Still, shares slipped 1.1% before the bell.

Key points: Regeneron shares recently traded around $580–$585 after a slight pullback earlier in the month investing.com. Over the past week REGN is up roughly 1–2%, recovering from a low in the high $570s investing.com. In its Oct. 28 earnings release, Regeneron reported Q3 2025 revenue of $3.75 billion, led by a 27% jump in Dupixent to $4.86 billion stocktitan.net. The company also won FDA approval for Libtayo in a high-risk skin cancer indication, and positive EU reviews for Libtayo and Dupixent stocktitan.net. Wall Street analysts have largely “buy” ratings on REGN: the consensus price target is about $725, implying ~25–27% upside tikr.com. The broader biotech sector has been rallying – for example, biotech ETFs are 25–34% higher since spring genengnews.com, outpacing the 24% gain in the S&P 500 over that span genengnews.com. Regeneron is still down from its 2024 highs, but recent drug wins and solid earnings are fueling renewed investor optimism.